Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Business & Industry
- Bayer launches LifeHub UK focused on artificial intelligence to optimize data-driven drug discovery and disease diagnosis
- Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
- The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
- Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
- Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
Research & Development
- First entirely digital clinical trial encourages physical activity
- New strategy to treat Parkinson's disease
- AI could offer warnings about serious side effects of drug-drug interactions
- Antibody-based eye drops show promise for treating dry eye disease
- Powerful new genomics method can be used to reveal the causes of rare genetic diseases
- AI and big data predict which research will influence future medical treatments
- Pharmacists provide patient value in team-based care
Conferences & Events
- 'FDA should withdraw ANDAs', and 'new technologies could bring massive improvements in efficiency' if implemented correctly
- SMi's 9th Annual Orphan Drugs & Rare Diseases Conference
- SMi's Inaugural Pharmaceutical Manufacturing & Cleanroom Technology Conference
- Disruptive Technologies in Pharma 2019
- Respiratory Drug Delivery 2019
- Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference
- eyeforpharma The Marketing Disruption Summit
Regulatory Affairs
- FDA approves new treatment for patients with migraine
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
- FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
- FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity
- FDA approves first oral GLP-1 treatment for type 2 diabetes